洞察市场格局
解锁药品研发情报

客服电话

400-9696-311
医药数据查询

2022年浙江新和成股份有限公司一季报

报告时间

2022-03-31

股票代码

002001.SZ

报告类型

季报

货币类型

CNY

营业收入

4,307,991,748.95

营业毛利润

1,789,897,201.68

净利润

1,207,852,620.67

报告附件
详细报告内容
Zhejiang NHU Company Ltd. Q1 2022 Report The Company and whole members of the BOD guarantee that the information disclosed is authentic, accurate, complete and free from any false records, misleading statements or significant omissions. Important Content Reminder: 1. The Board of Directors, Board of Supervisors, directors, supervisors and senior executives of Zhejiang NHU Company Ltd. (hereinafter referred to as the “Company”) hereby guarantee that the information presented in this report is authentic, accurate, complete and free of any false records, misleading statements or material omissions, and they will bear joint and several liabilities for such information. 2. The Company’s legal representative, the officer in charge of accounting, and the head of accounting department hereby declare and warrant that the financial information in this report is authentic, accurate and complete. 3. Whether the First Quarterly Report has been audited or not □ Yes √ No Note: This Report has been prepared in both Chinese and English version, and the English version is for reference only. Should there be any discrepancies or misunderstandings between the two versions, the Chinese versions shall prevail. The complete published Chinese First Quarterly Report may be obtained at www.cninfo.com.cn. Section Ⅰ KeyAccounting Data Ⅰ Key Accounting Data and Financial Indicators Whether the company needs performed retroactive adjustment or restatement of accounting data in prior years or not √ Yes □ No Retroactive adjustment or restatement of reasons Changes in accounting policies and other reasons Increase/decrease of the current reporting period Q1 2021 compared with the same Items Q1 2022 period of the previous year Before adjustment After After adjustment adjustment[Note2] Operating revenue (yuan) 4,307,991,748.95 3,743,831,818.61 3,790,255,566.08 13.66% Net profit attributable to shareholders of listed 1,203,327,294.72 1,136,774,983.04 1,144,090,085.76 5.18% company (yuan) Net profit attributable to shareholders of listed company after deducting 1,142,767,059.69 1,090,734,420.46 1,098,049,523.18 4.07% non-recurring profit or loss (yuan) Net cash flows from 422,441,679.66 1,076,704,398.64 1,084,019,501.36 -61.03% operating activities (yuan) Basic EPS (yuan/share) 0.47 0.44[Note1] 0.44 6.82% Diluted EPS (yuan/share) 0.47 0.44[Note1] 0.44 6.82% Weighted average ROE 5.36% 5.71% 5.75% Decreased by 0.39 percentage points Increase/decrease of the current reporting period Dec. 31, 2021 Items Mar. 31, 2022 compared with the end of the previous year Before adjustment After After adjustment adjustment[Note2] Total assets (yuan) 36,866,945,527.18 34,692,165,111.88 34,724,025,476.79 6.17% Net assets attributable to shareholders of listed 22,923,397,133.57 21,799,977,645.94 21,831,838,010.85 5.00% company (yuan) [Note1] After the implementation of the Company’s 2020 profit distribution plan, its share capital was increased from 2,148,662,300 shares to 2,578,394,760 shares. The above EPS of the comparative period was recalculated based on the adjusted share capital. [Note2] The company has implemented The Interpretation of Accounting Standards for Business Enterprises No. 15 since January 1, 2022. The interpretation requires that if the company sells the products or by-products produced before the fixed assets reach the expected serviceable state or during the research and development process, the income and cost related to the trial operation sales shall be accounted for separately and included in the current profit and loss, The net amount of the revenue from trial operation sales after offsetting the relevant costs shall not be used to offset the cost of fixed assets or R&D expenses. The company makes retroactive adjustment according to requirements. II Non-recurring Profit or Loss for this Period √Applicable □ Not applicable Unit: RMB yuan Items Q1 2022 Remarks Gains or losses on disposal of non-current assets, 4,679,172.59 including write-off of provision for impairment Government grants included in profit or loss (excluding those closely related to operating activities of the Company, satisfying government policies and regulations, 33,227,394.33 and continuously enjoyed with certain quantity or quota based on certain standards) Gains or losses on assets consigned to the third party for 8,305,996.39 investment or management Gains or losses on changes in fair value of held-for-trading financial assets and held-for-trading financial liabilities, and investment income from disposal of held-for-trading 16,998,294.74 financial assets and held-for-trading financial liabilities, excluding those arising from hedging business related to operating activities Other non-operating revenue or expenditures 1,012,255.32 Less: Enterprise income tax affected 3,636,037.36 Non-controlling interest affected (after tax) 26,840.98 Total 60,560,235.03 -- Details of other profit and loss items that meet the definition of non-recurring profit and loss □ Applicable √ Not applicable The Company does not have any other profit and loss items that meet the definition of non-recurring profit and loss. Explanation on defining the non-recurring profit and loss items listed in the No. 1 Explanatory Announcement on Information Disclosure for Companies Offering Their Securities to Public-Non-recurring Profit and loss as non-recurring profit and loss items. □ Applicable √ Not applicable The Company does not define the non-recurring profit and loss items listed in the No. 1 Explanatory Announcement on Information Disclosure for Companies Offering Their Securities to Public-Non-recurring Profit and loss as recurring profit and loss items. III Major Changes of Main Items in Financial Statements and Financial Indicators within the Reporting Period, as well as the Reasons for the Changes √ Applicable □Not applicable 1. Balance Sheet Position (1) The closing balance of advances paid increased by 38.54% compared to the closing balance at the beginning of the year. It was mainly due to the increase of prepayment in raw materials and fuel power in the current reporting period. (2) The closing balance of other current assets increased by 54.60% compared to the closing balance at the beginning of the year. It was mainly due to the increase in expenditure on purchasing financial products in the current reporting period. (3) The closing balance of other non-current assets increased by 31.28% compared to the closing balance at the beginning of the year. It was mainly due to the increase of prepayment in equipment in the current reporting period. (4) The closing balance of employee benefits payable decreased by 42.77% compared to the closing balance at the beginning of the year. It was mainly due to the payments on year-end bonuses in the current reporting period. (5) The closing balance of other current liabilities decreased by 40.15% compared to the closing balance at the beginning of the year. It was mainly due to the decrease of advance payments on sales in the current reporting period. (6) The closing balance of treasury shares increased by 35.00% compared to the closing balance at the beginning of the year. It was mainly due to the repurchase of part of companies’social public shares. (7) The closing balance of other comprehensive income decreased by 118.69% compared to the closing balance at the beginning of the year. It was mainly due to the difference of translating foreign currency financial statement. 2. Income Statement Position (1) R&D expenses in the current Q1 period increased by 42.50% compared to the same period of last year. It was mainly due to the increase of material inputs and salary in the current Q1 period. (2) Investment income in the current Q1 period increased by 447.44% compared to the same period of last year. It was mainly due to the increase of investment income in associated enterprises and the increase of delivery income of forward foreign exchange settlement and sales products in the current Q1 period. (3) Gains on changes in fair value in the current Q1 period increased by 47.08% compared to the same period of last year. It was mainly due to the fluctuation in exchange rate of undelivered forward foreign exchange settlement and sales
相关报告
序号
名称
操作
01
【2022】浙江新和成股份有限公司年报报告
02
【2022】浙江新和成股份有限公司三季报报告
03
【2022】浙江新和成股份有限公司中报报告
基于您的浏览,68%的用户还关注了【企业竞争格局】
获取更多浙江新和成股份有限公司竞争格局数据查看权限
立即前往摩熵医药企业版免费查询
示例数据
<END>
上市企业年报

最新企业动态资讯

摩熵医药企业版
50亿+条医药数据随时查
7天免费试用